Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms

Human Molecular Genetics

Volumn 23, Issue 2, 2014, Pages 555-561

  Bloom, A Joseph ^a   Baker, Timothy B ^b   Chen, Li Shiun ^a   Breslau, Naomi ^c   Hatsukami, Dorothy ^d   Bierut, Laura J ^a   Goate, Alison ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CYTOCHROME P450 2A6; EGLN2 PROTEIN; NICOTINE; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DISEASE RISK; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOXIA; METABOLISM; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO DEPENDENCE;

ANOXIA; ARYL HYDROCARBON HYDROXYLASES; CARBON MONOXIDE; CHROMOSOMES, HUMAN, PAIR 19; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; LINKAGE DISEQUILIBRIUM; NICOTINE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; TOBACCO USE DISORDER;

EID: 84895832391     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt432     Document Type: Article

References (72)

1. Mokdad, A.H., Marks, J.S., Stroup, D.F. and Gerberding, J.L. (2004) Actual causes of death in the United States, 2000. JAMA, 291, 1238-1245.
2. Sullivan, P.F. and Kendler, K.S. (1999) The genetic epidemiology of smoking. Nicotine Tob. Res., 1(Suppl. 2), S51-57. discussion S69-70.
3. Li, M.D. (2003) The genetics of smoking related behavior: a brief review. Am. J. Med. Sci., 326, 168-173.
4. Koopmans, J.R., Slutske, W.S., Heath, A.C., Neale, M.C. and Boomsma, D.I. (1999) The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins. Behav. Genet., 29, 383-393.
5. (2010) Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet., 42, 441-447.
6. Thorgeirsson, T.E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K.P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A. et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature, 452, 638-642.
7. Thorgeirsson, T.E., Gudbjartsson, D.F., Surakka, I., Vink, J.M., Amin, N., Geller, F., Sulem, P., Rafnar, T., Esko, T., Walter, S. et al. (2010) Sequence variants at CHRNB3-CHRNA6and CYP2A6 affect smoking behavior. Nat. Genet., 42, 448-453.
8. Saccone, S.F., Hinrichs, A.L., Saccone, N.L., Chase, G.A., Konvicka, K., Madden, P.A., Breslau, N., Johnson, E.O., Hatsukami, D., Pomerleau, O. et al. (2007) Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet., 16, 36-49.
9. Bierut, L.J., Stitzel, J.A., Wang, J.C., Hinrichs, A.L., Grucza, R.A., Xuei, X., Saccone, N.L., Saccone, S.F., Bertelsen, S., Fox, L. et al. (2008) Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiatry, 165, 1163-1171.
10. Chen, L.S., Baker, T.B., Piper, M.E., Breslau, N., Cannon, D.S., Doheny, K.F., Gogarten, S.M., Johnson, E.O., Saccone, N.L., Wang, J.C. et al. (2012) Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am. J. Psychiatry., 169, 735-742.
11. Freathy, R.M., Ring, S.M., Shields, B., Galobardes, B., Knight, B., Weedon, M.N., Smith, G.D., Frayling, T.M. and Hattersley, A.T. (2009) A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum. Mol. Genet., 18, 2922-2927.
12. Bierut, L.J., Madden, P.A., Breslau, N., Johnson, E.O., Hatsukami, D., Pomerleau, O.F., Swan, G.E., Rutter, J., Bertelsen, S., Fox, L. et al. (2007) Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum. Mol. Genet., 16, 24-35.
13. Malaiyandi, V., Sellers, E.M. and Tyndale, R.F. (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin. Pharmacol. Ther., 77, 145-158.
14. Benowitz, N.L., Swan, G.E., Jacob, P. III, Lessov-Schlaggar, C.N. and Tyndale, R.F. (2006)CYP2A6genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther., 80, 457-467.
15. Bloom, A.J., Harari, O., Martinez, M., Madden, P.A., Martin, N.G., Montgomery, G.W., Rice, J.P., Murphy, S.E., Bierut, L.J. and Goate, A. (2012) Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Hum. Mol. Genet., 21, 3050-3062.
16. Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A., Castagne, R., Maouche, S., Germain, M., Lackner, K., Rossmann, H. et al. (2010) Genetics and beyond-the transcriptome of human monocytes and disease susceptibility. PloS ONE, 5, e10693.
17. Goring, H.H., Curran, J.E., Johnson, M.P., Dyer, T.D., Charlesworth, J., Cole, S.A., Jowett, J.B., Abraham, L.J., Rainwater, D.L., Comuzzie, A.G. et al. (2007) Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat. Genet., 39, 1208-1216.
18. Cho, M.H., Castaldi, P.J., Wan, E.S., Siedlinski, M., Hersh, C.P., Demeo, D.L., Himes, B.E., Sylvia, J.S., Klanderman, B.J., Ziniti, J.P. et al. (2012) A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum. Mol. Genet., 21, 947-957.
19. Chen, L.S., Baker, T.B., Grucza, R., Wang, J.C., Johnson, E.O., Breslau, N., Hatsukami, D., Smith, S.S., Saccone, N., Saccone, S. et al. (2012) Dissection of the phenotypic and genotypic associations with nicotinic dependence. Nicotine Tob. Res., 14, 425-433.
20. Ho, M.K. and Tyndale, R.F. (2007) Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J, 7, 81-98.
21. Malaiyandi, V., Goodz, S.D., Sellers, E.M. and Tyndale, R.F. (2006) CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol. Biomarkers Prev., 15, 1812-1819.
22. Malaiyandi, V., Lerman, C., Benowitz, N.L., Jepson, C., Patterson, F. and Tyndale, R.F. (2006) Impact of CYP2A6genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry, 11, 400-409.
23. Benowitz, N.L., Pomerleau, O.F., Pomerleau, C.S. and Jacob, P. III. (2003) Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob. Res., 5, 621-624.
24. Lerman, C., Jepson, C., Wileyto, E.P., Patterson, F., Schnoll, R., Mroziewicz, M., Benowitz, N. and Tyndale, R.F. (2010) Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin. Pharmacol. Ther., 87, 553-557.
25. Patterson, F., Schnoll, R.A., Wileyto, E.P., Pinto, A., Epstein, L.H., Shields, P.G., Hawk, L.W., Tyndale, R.F., Benowitz, N. and Lerman, C. (2008) Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther., 84, 320-325.
26. Schnoll, R.A., Patterson, F., Wileyto, E.P., Tyndale, R.F., Benowitz, N. and Lerman, C. (2009) Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol. Biochem. Behav., 92, 6-11.
27. Benowitz, N.L., Jacob, P. III, Fong, I. and Gupta, S. (1994) Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther., 268, 296-303.
28. Bloom, J., Hinrichs, A.L., Wang, J.C., von Weymarn, L.B., Kharasch, E.D., Bierut, L.J., Goate, A. and Murphy, S.E. (2011) The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet. Genomics, 21, 403-416.
29. Koong, A.C., Denko, N.C., Hudson, K.M., Schindler, C., Swiersz, L., Koch, C., Evans, S., Ibrahim, H., Le, Q.T., Terris, D.J. et al. (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res., 60, 883-887.
30. Denko, N.C., Fontana, L.A.,Hudson, K.M., Sutphin, P.D., Raychaudhuri, S., Altman, R. and Giaccia, A.J. (2003) Investigating hypoxic tumor physiology through gene expression patterns. Oncogene, 22, 5907-5914.
31. Choi, Y.K., Kim, C.K., Lee, H., Jeoung, D., Ha, K.S., Kwon, Y.G., Kim, K.W. and Kim, Y.M. (2010) Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein. J. Biol. Chem., 285, 32116-32125.
32. Yu, H., Li, Q., Kolosov, V.P., Perelman, J.M. and Zhou, X. (2011) Regulation of cigarette smoke-mediated mucin expression by hypoxia-inducible factor-1alpha via epidermal growth factor receptor-mediated signaling pathways. J. Appl. Toxicol., 32, 282-292.
33. Greer, S.N., Metcalf, J.L., Wang, Y. and Ohh, M. (2012) The updated biology of hypoxia-inducible factor. EMBO J., 31, 2448-2460.
34. Majmundar, A.J., Wong, W.J. and Simon, M.C. (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell, 40, 294-309.
35. Webb, J.D., Coleman, M.L. and Pugh, C.W. (2009) Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell. Mol. Life Sci., 66, 3539-3554.
36. Metzen, E. and Ratcliffe, P.J. (2004) HIF hydroxylation and cellular oxygen sensing. Biol. Chem., 385, 223-230.
37. Zhang, Q., Gu, J., Li, L., Liu, J., Luo, B., Cheung, H.W., Boehm, J.S., Ni, M., Geisen, C., Root, D.E. et al. (2009) Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell, 16, 413-424.
38. Cummins, E.P., Berra, E., Comerford, K.M., Ginouves, A., Fitzgerald, K.T., Seeballuck, F., Godson, C., Nielsen, J.E., Moynagh, P., Pouyssegur, J. et al. (2006) Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl Acad. Sci. USA, 103, 18154-18159.
39. Siddiq, A., Aminova, L.R., Troy, C.M., Suh, K., Messer, Z., Semenza, G.L. and Ratan, R.R. (2009) Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-and CREB-independent pathways. J. Neurosci., 29, 8828-8838.
40. Anderson, K., Nordquist, K.A., Gao, X., Hicks, K.C., Zhai, B., Gygi, S.P. and Patel, T.B. (2011) Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. J. Biol. Chem., 286, 42027-42036.
41. Takeda, K., Ho, V.C., Takeda, H., Duan, L.J., Nagy, A. and Fong, G.H. (2006) Placental but not heart defects are associated with elevated 560 Human Molecular Genetics, 2014, Vo. 23, No. 2 hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol., 26, 8336-8346.
42. Aragones, J., Schneider, M., Van Geyte, K., Fraisl, P., Dresselaers, T., Mazzone, M., Dirkx, R., Zacchigna, S., Lemieux, H., Jeoung, N.H. et al. (2008) Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet., 40, 170-180.
43. Ho, M.K., Faseru, B., Choi, W.S., Nollen, N.L., Mayo, M.S., Thomas, J.L., Okuyemi, K.S., Ahluwalia, J.S., Benowitz, N.L. and Tyndale, R.F. (2009) Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiol. Biomarkers Prev., 18, 3426-3434.
44. Frei, M., Engel Brugger, O., Sendi, P., Reichart, P.A., Ramseier, C.A. and Bornstein, M.M. (2012) Assessment of smoking behaviour in the dental setting. A study comparing self-reported questionnaire data and exhaled carbon monoxide levels. Clin. Oral Investig., 16, 755-760.
45. Dickson, S.P., Wang, K., Krantz, I., Hakonarson, H. and Goldstein, D.B. (2010) Rare variants create synthetic genome-wide associations. PLoS Biol., 8, e1000294.
46. Bloom, A.J., Harari, O., Martinez, M., Zhang, X., McDonald, S.A., Murphy, S.E. and Goate, A. (2013) A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele. Pharmacogenet. Genomics. in press.
47. Krall, E.A., Valadian, I., Dwyer, J.T. and Gardner, J. (1989) Accuracy of recalled smoking data. Am. J. Public Health, 79, 200-202.
48. Vesey, C.J., Saloojee, Y., Cole, P.V. and Russell, M.A. (1982) Blood carboxyhaemoglobin, plasma thiocyanate, and cigarette consumption: implications for epidemiological studies in smokers. Br. Med. J. (Clin. Res. Ed.), 284, 1516-1518.
49. Etter, J.F. and Perneger, T.V. (2001) Measurement of self reported active exposure to cigarette smoke. J. Epidemiol. Community Health, 55, 674-680.
50. Etter, J.F., Vu Duc, T. and Perneger, T.V. (2000) Saliva cotinine levels in smokers and nonsmokers. Am. J. Epidemiol., 151, 251-258.
51. Perez-Stable, E.J., Benowitz, N.L. and Marin, G. (1995) Is serum cotinine a better measure of cigarette smoking than self-report? Prev. Med., 24, 171-179.
52. Scherer, G. (2006) Carboxyhemoglobin and thiocyanate as biomarkers of exposure to carbon monoxide and hydrogen cyanide in tobacco smoke. Exp. Toxicol. Pathol., 58, 101-124.
53. Domino, E.F. and Ni, L. (2002) Clinical phenotyping strategies in selection of tobacco smokers for future genotyping studies. Prog. Neuropsychopharmacol. Biol. Psych., 26, 1071-1078.
54. Marrone, G.F., Paulpillai, M., Evans, R.J., Singleton, E.G. and Heishman, S.J. (2010) Breath carbon monoxide and semiquantitative saliva cotinine as biomarkers for smoking. Hum. Psychopharmacol., 25, 80-83.
55. Wood, T., Wewers, M.E., Groner, J. and Ahijevych, K. (2004) Smoke constituent exposure and smoking topography of adolescent daily cigarette smokers. Nicotine Tob. Res., 6, 853-862.
56. Joseph, A.M., Hecht, S.S., Murphy, S.E., Carmella, S.G., Le, C.T., Zhang, Y., Han, S. and Hatsukami, D.K. (2005) Relationships between cigarette consumption and biomarkers of tobacco toxin exposure. Cancer Epidemiol. Biomarkers Prev., 14, 2963-2968.
57. Arndt, J., Vail, K.E. III, Cox, C.R., Goldenberg, J.L., Piasecki, T.M. and Gibbons, F.X. (2013) The interactive effect of mortality reminders and tobacco craving on smoking topography. Health Psychol., 32, 525-532.
58. Perkins, K.A., Karelitz, J.L., Giedgowd, G.E. and Conklin, C.A. (2012) The reliability of pufftopography and subjective responses during ad lib smoking of a single cigarette. Nicotine Tob. Res., 14, 490-494.
59. Stewart, D.W., Vinci, C., Adams, C.E., Cohen, A.S. and Copeland, A.L. (2013) Smoking topography and outcome expectancies among individuals with schizotypy. Psychiatry Res., 205, 205-212.
60. Hung, R.J., McKay, J.D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P. et al. (2008)Asusceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 452, 633-637.
61. Amos, C.I., Wu, X., Broderick, P., Gorlov, I.P., Gu, J., Eisen, T., Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J. et al. (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet., 40, 616-622.
62. VanderWeele, T.J., Asomaning, K., Tchetgen Tchetgen, E.J., Han, Y., Spitz, M.R., Shete, S., Wu, X., Gaborieau, V., Wang, Y., McLaughlin, J. et al. (2012) Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am. J. Epidemiol., 175, 1013-1020.
63. Le Marchand, L., Derby, K.S., Murphy, S.E., Hecht, S.S., Hatsukami, D., Carmella, S.G., Tiirikainen, M. and Wang, H. (2008) Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res., 68, 9137-9140.
64. Wassenaar, C.A., Dong, Q., Wei, Q., Amos, C.I., Spitz, M.R. and Tyndale, R.F. (2011) Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J. Natl. Cancer Inst., 103, 1342-1346.
65. Piper, M.E., Federman, E.B., McCarthy, D.E., Bolt, D.M., Smith, S.S., Fiore, M.C. and Baker, T.B. (2007) Efficacy of bupropion alone and in combination with nicotine gum. Nicotine Tob. Res., 9, 947-954.
66. McCarthy,D.E., Piasecki, T.M., Lawrence,D.L., Jorenby,D.E., Shiffman, S., Fiore, M.C. and Baker, T.B. (2008) A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob. Res., 10, 717-729.
67. Piper, M.E., Smith, S.S., Schlam, T.R., Fiore, M.C., Jorenby, D.E., Fraser, D. and Baker, T.B. (2009) A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch. Gen. Psychiatry, 66, 1253-1262.
68. Heatherton, T.F., Kozlowski, L.T., Frecker, R.C. and Fagerstrom, K.O. (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict., 86, 1119-1127.
69. Saccone, N.L., Saccone, S.F., Hinrichs, A.L., Stitzel, J.A., Duan, W., Pergadia, M.L., Agrawal, A., Breslau, N., Grucza, R.A., Hatsukami, D. et al. (2009) Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am. J. Med. Genet. B Neuropsychiatr. Genet., 150B, 453-466.
70. Saccone, N.L., Wang, J.C., Breslau, N., Johnson, E.O., Hatsukami, D., Saccone, S.F., Grucza, R.A., Sun, L., Duan, W., Budde, J. et al. (2009) The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res., 69, 6848-6856.
71. Gauderman,W. and Morrison, J. (2006) Quanto 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. http : //hydra.Usc.Edu/gxe.
72. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.